Immatics (NASDAQ:IMTX) Sees Large Volume Increase

Immatics (NASDAQ:IMTXGet Free Report) saw an uptick in trading volume on Tuesday . 566,980 shares traded hands during mid-day trading, an increase of 14% from the previous session’s volume of 495,542 shares.The stock last traded at $11.85 and had previously closed at $11.83.

Immatics Trading Up 3.3 %

The company has a fifty day simple moving average of $11.83 and a 200-day simple moving average of $10.59. The company has a market capitalization of $1.02 billion, a PE ratio of -10.07 and a beta of 0.69.

Hedge Funds Weigh In On Immatics

A number of hedge funds have recently modified their holdings of the business. Virtus ETF Advisers LLC grew its holdings in shares of Immatics by 14.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,447 shares of the company’s stock worth $99,000 after purchasing an additional 1,184 shares during the period. Trexquant Investment LP grew its holdings in shares of Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after purchasing an additional 1,801 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Immatics by 3.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 68,219 shares of the company’s stock worth $718,000 after purchasing an additional 2,300 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Immatics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock worth $121,000 after purchasing an additional 2,916 shares during the period. Finally, BlackRock Inc. purchased a new position in shares of Immatics during the 1st quarter worth $27,000. 53.42% of the stock is currently owned by hedge funds and other institutional investors.

About Immatics

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Recommended Stories

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.